Metformin (Glucophage) disrupts normal metabolism and causes lactic acidosis (automatically, by blocking the Cori cycle).

Original statement

أدوية مثل الجلوكوفاج والفورسيجا تعطّل العمليات الأيضية الطبيعية للجسم، وتتسبب في مضاعفات مثل الحماض اللاكتيكي أو الكيتوني.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Metformin (Glucophage) disrupts normal metabolism and causes lactic acidosis (automatically, by blocking the Cori cycle).

Origin

Source status

Archive quote (no location given)

Attribution

Elawady (archive paraphrase; source video not given)

Origin

https://eltayebat.com/rule/oral-diabetes-drugs/

Attribution uncertainty

The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. 'Glucophage causes acidity in the blood' is found (5QU3gO-o0Mg). The mechanism 'by blocking the Cori cycle' was not checked verbatim.

Claimed mechanism

Metformin inhibits hepatic gluconeogenesis from lactate (Cori cycle), so lactate accumulates.

Claimed health effect

Lactic acidosis

Population concerned

Metformin users

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.

Certainty of evidence: high – Further research is very unlikely to change the assessment.

1. What was claimed?

Metformin causes lactic acidosis.

2. What is demonstrably correct?

Metformin lowers hepatic glucose production; in situations of severe kidney failure, shock or hypoxia it can accumulate, and labels advise caution. ADA 2026 advises considering holding metformin when oral intake cannot be maintained (I-INS-10).

3. What is wrong or exaggerated?

Cochrane: 'no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use'; upper limit 4.3 vs 5.4 cases per 100,000 patient-years for non-metformin; no difference in lactate levels (I-ODD-08). Metformin reduced all-cause mortality by 36% in overweight patients in UKPDS 34 (I-ODD-01) and was associated with lower mortality at 10 years (I-INS-02). The archive's own cited cohorts used metformin as the reference with the lowest risk (A-INS-08, A-ODD-07).

4. What remains unclear?

Exact incidence in people with advanced kidney disease.

5. Which studies support it?

Mechanism; label warnings; association with acidosis at eGFR <30 (HR 2.07) in a large cohort (I-ODD-101); ADA 2026 (I-INS-10, I-ODD-16).

6. Which studies contradict it?

I-ODD-08 (Cochrane: no cases in 70,490 patient-years), I-ODD-102 (incidence 3-10/100,000 PY, like background), I-ODD-101 (no association at eGFR >=30), I-ODD-01, I-INS-02.

7. What applies to Germany and Europe?

Metformin is first-line therapy in EU/German guidelines with eGFR-based dose limits.

8. What is known about Egypt?

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. What practical conclusion is appropriate?

Metformin-associated lactic acidosis is very rare and mostly linked to contraindicated situations. Metformin is one of the safest and best-studied diabetes drugs; B12 should be checked periodically (see C-ODD-07).

Assessment details

Rationale for certainty of evidence

Mechanistic kernel (metformin reduces hepatic gluconeogenesis, including from lactate) and rare cases, mainly with severe kidney failure, hypoxia or overdose, are real. A Cochrane review of 347 trials/cohorts (70,490 patient-years) found no case of lactic acidosis and no difference in lactate (I-ODD-08); a systematic review puts the incidence at about 3-10 per 100,000 patient-years, indistinguishable from background (I-ODD-102); a cohort of 75,413 patients with time-updated kidney function found no association at eGFR >=30 (HR 0.98) and an association only at eGFR <30 (HR 2.07) (I-ODD-101). ADA 2026 states the complication is very rare and occurs primarily at eGFR <30. The evidence is consistent and precise, so certainty is high that lactic acidosis is not an automatic effect.

Source quality

Archive paraphrase plus own words.

Regional transferability

Universal.

Individual exceptions

Severe kidney impairment, shock, hypoxia, alcohol excess and contrast/surgery situations require dose adjustment or pausing.

Regional scope of the claim

general (biological/medical)

Last reviewed

26 October 2026 provisional

Scientific evidence in detail

Scientifically refuted – High-quality evidence shows the opposite, or the claim contradicts well-established physiology.

Research question: In people with type 2 diabetes, does metformin use cause lactic acidosis regularly ('automatically'), and how large is the risk compared with other glucose-lowering treatment across levels of kidney function?

Study results as reported by the authors. Our assessment follows below.

Open questions

Risk during prolonged fasting with dehydration has not been quantified.

How deeply was this checked?

7 linked studies: 2 checked in full text (0 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

In plain language

Metformin has a theoretical risk of acid build-up in the blood, mainly in people with very poor kidney function or severe illness. A large review of more than 300 studies found no such cases in about 70,000 patient-years. In a long British study, metformin users lived longer. Doctors adjust or pause metformin when kidneys fail or during serious illness.

Studies on this claim

Regional context

Germany / EU

Metformin is first-line therapy in EU/German guidelines with eGFR-based dose limits.

Egypt

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

What applies in my country?

General scientific assessment

Mostly false Mostly false: lactic acidosis from metformin is very rare (about 3-10 per 100,000 patient-years) and occurs mainly with severe kidney failure, overdose or shock, not automatically.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
2. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.. Salpeter SR et al.. Cochrane Database Syst Rev 2010 · PMID 20393934 · DOI 10.1002/14651858.CD002967.pub4
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742977
4. 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
5. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
6. Metformin in patients with type 2 diabetes and kidney disease: a systematic review.. Inzucchi SE et al.. JAMA 2014 · PMID 25536258 · DOI 10.1001/jama.2014.15298
7. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.. Lazarus B et al.. JAMA Intern Med 2018 · PMID 29868840 · DOI 10.1001/jamainternmed.2018.0292